Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06671483 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06671483 · ClinicalTrials.gov record · last posted 2026-08-11

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

StatusRecruiting
PhasePhase 3
SponsorTakeda
Started2025-03-03
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.

Amendment record 20 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 20 times since 2024-10-31; most recent amendment 2026-06-26. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-03-04
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT06671483
Lead Sponsor Takeda
Conditions Psoriatic Arthritis
Enrollment 1,088 participants
Start Date 2025-03-03
Primary Completion 2027-05-18 (estimated)
Study Completion 2028-01-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-11